AstraZeneca and Tempus AI Renew $200 Million Oncology Collaboration for AI-Driven Drug Discovery
Trendline

AstraZeneca and Tempus AI Renew $200 Million Oncology Collaboration for AI-Driven Drug Discovery

What's Happening? AstraZeneca and Tempus AI have renewed and expanded their strategic oncology collaboration for another five years, with AstraZeneca committing $200 million to advance cancer drug discovery and development through artificial intelligence and multimodal data. The agreement, signed on
AI Generated
This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.